Member Info for MrJinx

If I’m reading that right, Kelonia have made positive steps forward with the treatment of Multiple Myeloma. Now I know you’re quite dim Alldimbrain, so I’m not sure if you read past the Twitter post, but that’s not AML.

For clarification;

Multiple Myeloma and Acute Myeloid Leukemia (AML) are not the same; they are two different types of blood cancer with distinct cellular origins. Multiple myeloma is a cancer of plasma cells in the bone marrow, while AML is a cancer of immature myeloid cells, also originating in the bone marrow.

Obviously you weren’t trying to mislead people, were you?

Lol…why, indeed. 🤨

You’re full of $hit ‘dimbrain.

I’m not really sure what NumptyPoster and Alldimbrain think they have found. It’s always been the case if Hemo didn’t find a JV Partner/Licensing/buyout deal, then we’d need to raise money. It’s not rocket science. So the two options are, we get a partner to fund the trials potentially resulting in a multi-billion dollar deal, or we fund it through the trials ourselves, resulting in potentially a 100% owned multi-billion dollar treatment for AML.

How is that different to any other small bio still in the research/trial stage of a treatment? To be honest, if Hemo got to the finish line, 100% owned, for a further £20-25m, I’d be ecstatic…and retired.

‘Whether’, yer dumbo.

Should anyone want to read the actual Prospectus, it is here: https://hemogenyx.com/wp-content/uploads/2025/11/Hemogenyx-Pharmaceuticals-plc-Prospectus-20251119.pdf

Lol, I understand anecdote isn’t data, yer numbskull 😂

lol…alldimbrain making stuff up again. where does it say in any helpful guide that there needs to be ‘5x volume to clear shares’ ? you’ve totally made that **** up. a bit like most of your attempts at spelling.

Google Ai thinks we’re smokin’…

“ Stock price predictions for Hemogenyx Pharmaceuticals Plc (HEMO) vary, but the consensus from analysts is an "Outperform" rating with a potential significant upside from its current price. The stock is traded on the London Stock Exchange (LSE).

Analyst Price Targets

Based on the one-year price targets from analysts:

Average Target Price: £278.42

High Estimate: £325.00

Low Estimate: £209.34

The current price is significantly below the average target, implying a large potential upside according to these forecasts.

That 13.6 months is a very targeted group that would have been pre-screened to achieve a ‘better outcome’. It also does not include testament of quality of life or the duration of response. If it’s similar to the research paper I read, further relapse occurred within 3-9 months and most of the 13.6 months you state, was spent in a Clinical Care receiving environment.

Indeed, if you look at overall survival rates, collating all clinical approaches to R/R AML, the survival time is drastically less than 13.6 months. I think it’s something like 6 months.

Out of 25 posts on the first page of the Hemo discussion board, NotPosting has posted 13 of them. He/She isn’t even invested here so that in itself is a measure of how ‘not quite right in the head’ they are. They’re either mentally unwell, very lonely or just a personality filled with utter poison. I hope his/her situation improves very soon.

Hate to be a pedant but ‘most’ aren’t underwater here. Some undoubtedly are as they bought upwards to £15 and £16plus. But that doesn’t mean they’re not going to make shed loads, possibly within the next six to twelve months. Nobody can do much about other people buying and selling so why gripe? If you believe this is a first in class, groundbreaking treatment and history has shown other Car-T treatments be worth £Billions, then why would anyone give two shiits about short-term price movements?

He won’t name them, because he can’t.

Alldimbrain “it’s a low IQ board”, but then still can’t recognise his own spelling mistakes. ‘Big Farmer…’ Hahaha oh my days hahaha…I think I’ve wet myself… hahaha 🤣

What a dolt!

I can’t see the news being 4th patient treated until at least December, possibly Jan 26. Vlad himself stated there was going to be a delay in next treatments due to transferring all manufacturing to Made Scientific. He also said something about ‘trade secrets’ which was a bit waffly.

Snooker1000…? I’m going to have a guess at Tuan. Is there a prize if I’m right?

Delano, aren’t you back at School Monday?

Faron…you mean the Faron that has a share price of nearly £200 and a MCap of over £200m…? That Faron?

Oh my god! The idiots that frequent this board. Sweet baby Jesus!

Wtf are you talking about you buffoon. Crikey, even if I wasn’t a medical professional, I can Google the crap out of it for you, if you still think it’s brain surgery! 😂